Michelle Chang

Michelle Chang

Professor of Biochemistry, Biophysics and Structural Biology*
*and of Chemistry

Lab Homepage: http://www.cchem.berkeley.edu/mccgrp/

Env Full Directory Information

Research Interests

Biochemistry, Enzymology, and Synthetic Biology

Our research laboratory utilizes the approaches of mechanistic biochemistry, molecular and cell biology, metabolic engineering, and synthetic biology to address problems in energy and human health. We design and create new biosynthetic pathways in microbial hosts for in vivo production of biofuels from abundant crop feedstocks and pharmaceuticals from natural products or natural product scaffolds. A unifying theme of all of our projects is a focus on gaining a detailed molecular understanding of how chemistry occurs in living cells and how to exploit unique metabolic pathways for new applications.

Current Projects

Biofuels. Sustainable energy is a significant challenge facing our planet and securing carbon-neutral sources of energy is essential to meeting growing energy demands while addressing environmental concerns. Energy and fuels produced from plant biomass offer an important renewable solution to this problem and also allow reduction in the overall release of greenhouse gases. We are constructing new biosynthetic pathways in bacterial hosts that can convert plant biomass into fuel molecules. Using synthetic biology methods, we can draw enzymes from a variety of different environmental organisms and combine them in a single genetically-engineered host. This mix-and-match approach allows us to create and tailor new biological tools for multi-step, multi-enzyme chemical synthesis.

Enzymatic Fluorinations. Natural products and their scaffolds continue to provide a rich source for the discovery and development of new therapeutics to treat human conditions ranging from cancer to neurodegeneration to microbial infections. In this regard, halogenated natural products (vancomycin and chloramphenicol) as well as synthetic drugs (Prozac, Lipitor, Cipro) encompass a growing class of important organohalogen-based pharmaceuticals. Organofluorine compounds are of particular interest as the introduction of C-F bonds can tune drug activity and specificity as well as in vivo metabolism of drugs. However, one of the major limitations in drug development is ability to selectively form C-F bonds as the available chemical methods for fluorination are difficult and typically carried out with harsh reagents without sufficient control over regio- or stereospecificity. We are developing new biocatalysts and metabolic pathways for selective and efficient C-F bond formation under mild conditions through the isolation, characterization, and mechanistic investigation of new enzymes involved in biological halogenations.

Selected Publications

MCY Chang (2007) Harnessing energy from plant biomass. Curr. Opin. Chem. Biol. 11, 677-684.

MCY Chang, RA Eachus, W Trieu , D-K Ro, and JD Keasling (2007) Engineering Escherichia coli for production of functionalized terpenoids using plant P450s. Nat. Chem. Biol. 3, 274-277.

MCY Chang and JD Keasling (2006) Production of isoprenoid pharmaceuticals by engineered microbes”, Nat. Chem. Biol. 2, 674-681.

MCY Chang, CS Yee, DG Nocera, and J Stubbe (2004) Site-specific replacement of a conserved tyrosine in ribonucleotide reductase with an aniline amino acid: A mechanistic probe for redox-active tyrosines. J. Am. Chem. Soc. 126, 16702-16703.

MCY Chang, CS Yee, J Stubbe, and DG Nocera (2004) Turning on ribonucleotide reductase by light-initiated radical generation. Proc. Natl. Acad. Sci. USA 101, 6882-6887.



Photo credit: Mark Joseph Hanson of Mark Joseph Studio.

Last Updated 2009-06-23